These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28393307)

  • 1. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses.
    Valdés I; Marcos E; Suzarte E; Pérez Y; Brown E; Lazo L; Cobas K; Yaugel M; Rodríguez Y; Gil L; Guillén G; Hermida L
    Arch Virol; 2017 Aug; 162(8):2247-2256. PubMed ID: 28393307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
    Zuest R; Valdes I; Skibinski D; Lin Y; Toh YX; Chan K; Hermida L; Connolly J; Guillen G; Fink K
    Vaccine; 2015 Mar; 33(12):1474-82. PubMed ID: 25659270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation in Mice of the Immunogenicity of a Tetravalent Subunit Vaccine Candidate Against Dengue Virus Using Mucosal and Parenteral Immunization Routes.
    Lazo Vázquez L; Gil González L; Marcos López E; Pérez Fuentes Y; Cervetto de Armas L; Brown Richards E; Valdés Prado I; Suzarte Portal E; Cobas Acosta K; Yaugel Novoa M; Romero Fernández Y; Guillén Nieto G; Hermida Cruz L
    Viral Immunol; 2017 Jun; 30(5):350-358. PubMed ID: 28418786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.
    Gil L; Marcos E; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Hitler R; Suzarte E; Álvarez M; Kimiti P; Ndung'u J; Kariuki T; Guzmán MG; Guillén G; Hermida L
    Immunol Cell Biol; 2015 Jan; 93(1):57-66. PubMed ID: 25178969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
    Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
    Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
    Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
    Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
    Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
    Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
    Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
    Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
    Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
    Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus.
    Marcos E; Gil L; Lazo L; Izquierdo A; Brown E; Suzarte E; Valdés I; García A; Méndez L; Guzmán MG; Guillén G; Hermida L
    Arch Virol; 2013 Jan; 158(1):225-30. PubMed ID: 22983185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
    Lazo L; Gil L; López C; Valdés I; Blanco A; Pavón A; Romero Y; Guzmán MG; Guillén G; Hermida L
    Acta Trop; 2012 Nov; 124(2):107-12. PubMed ID: 22750482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys.
    Gil L; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Marcos E; Suzarte E; Kariuki T; Guzmán G; Guillén G; Hermida L
    Virology; 2014 May; 456-457():70-6. PubMed ID: 24889226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity.
    Chiang CY; Hsieh CH; Chen MY; Tsai JP; Liu HH; Liu SJ; Chong P; Leng CH; Chen HW
    Vaccine; 2014 Mar; 32(12):1346-53. PubMed ID: 24486311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
    Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
    Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
    Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
    Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-response study in mice of a tetravalent recombinant dengue envelope domain III protein secreted from insect cells.
    Shao L; Pang Z; Bi Y; Li Z; Lin W; Li G; Guo Y; Qi J; Niu G
    Infect Genet Evol; 2020 Nov; 85():104427. PubMed ID: 32565359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.